pimecrolimus (Elidel)

an ascomycin derivative; mechanism of action involves calcineurin inhibition, blockage of T cell activation, blocking signal transduction pathways in T cells, and inhibition of the synthesis of inflammatory cytokines, specifically Th1- and Th2-type cytokines

Also Known As:

Networked: 502 relevant articles (142 outcomes, 153 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bräutigam, Matthias: 15 articles (09/2013 - 01/2002)
2.	Stuetz, Anton: 12 articles (09/2008 - 10/2002)
3.	Eichenfield, Lawrence F: 11 articles (12/2015 - 04/2002)
4.	Paul, Carle: 11 articles (06/2015 - 07/2002)
5.	Fölster-Holst, Regina: 10 articles (06/2015 - 01/2002)
6.	Boguniewicz, Mark: 9 articles (12/2015 - 04/2002)
7.	Meurer, Michael: 9 articles (06/2012 - 01/2002)
8.	Prous, J R: 9 articles (09/2007 - 01/2003)
9.	Rabasseda, X: 9 articles (09/2007 - 01/2003)
10.	Luger, Thomas: 8 articles (06/2015 - 01/2003)

Related Diseases

1.	Atopic Dermatitis (Atopic Eczema) 01/01/2006 - "Pimecrolimus cream 1% has proven to be well tolerated, safe, and highly effective in clinical studies in patients with atopic dermatitis." 10/01/2007 - "Pimecrolimus cream 1% has proven to be well-tolerated and effective in controlled clinical studies in patients with atopic dermatitis (AD). " 04/01/2006 - "The present study demonstrates that the good efficacy and tolerability of pimecrolimus ointment which had been shown in controlled trials: i) could also be demonstrated on a very large cohort of patients with atopic dermatitis when used in the outpatient setting, and ii) were paralleled by a significant improvement in the quality of life." 10/01/2005 - "In multiple clinical trials comprising more than 19,000 patients, pimecrolimus cream has been shown to be very effective in suppressing atopic dermatitis and to have an excellent safety profile. " 11/01/2004 - "Pimecrolimus cream 1% was well tolerated and effective in patients with mild to very severe atopic eczema, with rapid onset of action and no disease rebound after discontinuation."
2.	Psoriasis (Pustulosis Palmaris et Plantaris) 03/01/2004 - "Short-term, Phase I/II and Phase II trials of pimecrolimus administered orally in psoriasis and AD have shown that this drug is highly effective in a dose-dependent manner in patients with these diseases and has high safety profile. " 10/01/2002 - "We conclude that pimecrolimus taken orally is highly effective in a concentration-dependent manner in patients with psoriasis and on a short-term basis it is well tolerated and this is confirmed by its pharmacogenomic profile. " 10/01/2002 - "Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated." 11/01/2004 - "Pimecrolimus cream 1% is an effective treatment for inverse psoriasis with a rapid onset of action, and is safe and well-tolerated." 03/01/2009 - "Pimecrolimus 1% cream is effective in the treatment of psoriasis in an infant."
3.	Dermatitis 11/01/2007 - "Significantly more pimecrolimus-treated patients than vehicle-treated patients achieved clearance of eyelid dermatitis (45% vs. 19%, respectively). " 11/01/2007 - "Pimecrolimus cream 1% is effective in patients with head and neck dermatitis intolerant of, or dependent on, TCS. " 01/01/2003 - "Twice daily topical treatment of moderate to severe chronic hand dermatitis with pimecrolimus cream 1% results in low pimecrolimus blood levels, is well tolerated, safe, and effective." 01/01/2003 - "Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. " 01/01/2004 - "Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis."
4.	Eczema 01/01/2007 - "Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients." 01/01/2007 - "Pimecrolimus cream 1% is effective in patients with asteatotic eczema." 01/01/2004 - "In the published studies on the efficacy of the topical immunomodulator pimecrolimus, different eczema scores were used, and the impact on morphological key signs of eczema was not analysed. " 01/01/2007 - "Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema." 01/01/2007 - "Randomised controlled trials of 1.0% topical pimecrolimus used twice daily compared against other topical comparators for treating eczema. "
5.	Pruritus (Itching) 01/01/2007 - "Pimecrolimus cream 1% improved pruritus within 48 hours in children and adolescents with mild to moderate AD and achieved complete resolution of pruritus in a significantly greater number of subjects in the pimecrolimus group versus the vehicle group by the end of the 7-day treatment period (P = .008)." 08/01/2010 - "Pruritus relief, however, was significantly greater in the pimecrolimus group." 01/01/2007 - "In the per-protocol (PP) population, median times to a 1 point or more improvement in pruritus score were 48 and 72 hours for pimecrolimus and vehicle groups, respectively (P = .038). " 01/01/2007 - "The objective of this study was to assess time to onset of pruritus improvement in a pediatric population treated with pimecrolimus cream 1%. " 01/01/2006 - "A single-centre, non-controlled, open-label study was designed to assess the efficacy of topical pimecrolimus in the treatment of chronic vulvar pruritus. "

Related Drugs and Biologics

1.	pimecrolimus (Elidel)
2.	Tacrolimus (Prograf)
3.	Adrenal Cortex Hormones (Corticosteroids)
4.	Calcineurin
5.	Cytokines
6.	immunomycin (ascomycin)
7.	Clobetasol (Clobetasol Propionate)
8.	Betamethasone (Celestone)
9.	Hydrocortisone (Cortisol)
10.	Steroids

Related Therapies and Procedures

1.	Off-Label Use
2.	Dye Lasers
3.	Stents
4.	Laminectomy
5.	Phototherapy (Light Therapy)